Last reviewed · How we verify
Inderal (propranolol)
Propranolol (Inderal) was the first successful beta-blocker, developed by Nobel laureate Sir James Black and approved in 1967. Now available generically, it has one of the broadest indication profiles of any cardiovascular drug.
At a glance
| Generic name | propranolol |
|---|---|
| Also known as | Inderal, Inderal LA |
| Sponsor | Generic (originally ICI/AstraZeneca) |
| Drug class | Non-selective beta-blocker |
| Target | Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1967-11-13 (United States) |
Approved indications
- Angina pectoris
- Arrhythmias During Surgery
- Atrial fibrillation
- Essential tremor
- Haemangioma with a risk of permanent scars or disfigurement
- Hemangioma
- Hypertensive disorder
- Hypertrophic cardiomyopathy
- Idiopathic hypertrophic subaortic stenosis
- Life or functionthreatening haemangioma
- Life-Threatening Ventricular Tachycardia
- Migraine Prevention
- Myocardial Reinfarction Prevention
- Pheochromocytoma Adjunct Therapy
- Proliferating infantile haemangioma requiring systemic therapy
- Supraventricular tachycardia
- Ulcerated haemangioma
Common side effects
- Sleep disorders
- Aggravated respiratory tract infections
- Diarrhea
- Vomiting
Serious adverse events
- Hypoglycemia
- Hypoglycemic seizure
- Bronchospasm
- Second degree atrioventricular heart block
- Decreased blood glucose
- Decreased heart rate
- Agranulocytosis
- Hallucination
- Purpura
- Dermatitis psoriasiform
Drug interactions
- Propafenone
- Quinidine
- Amiodarone
- Lidocaine
- Digitalis Glycosides
- Calcium Channel Blockers
- ACE Inhibitors
- Clonidine
- Prazosin
- Terazosin
- Doxazosin
- Reserpine
Key clinical trials
- Evaluation of Gastrointestinal Transite in Cirrhotic Patient Pre and Post Treatment With Non Selective Betablockers (Propanolol) (NA)
- Comparing Standard vs. Modified Reconsolidation Blockade for the Treatment of Psychological Trauma: A Randomized Controlled Trial (Phase 2)
- Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy (Phase 1)
- Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma (Phase 4)
- Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome (Phase 2)
- Efficacy of Propanolol for Treatment of Posttraumatic Stress Disorder (Phase 4)
- A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alo (Phase 3)
- Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine) (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inderal CI brief — competitive landscape report
- Inderal updates RSS · CI watch RSS
- Generic (originally ICI/AstraZeneca) portfolio CI